Fibromyalgia is clinically defined as "a syndrome consisting of chronic symptoms of moderate to severe intensity including diffuse chronic pain without apparent cause and sensitivity to pressure, associated with fatigue, cognitive and sleep disorders and numerous complaints somatic”. It was recognized as a medical entity by the World Health Organization (WHO) in 1992 and classified as generalized chronic pain in the latest International Classification of Diseases (ICD).
Despite this institutional recognition, the disease is still the subject of controversy. The heterogeneity of its symptoms and the absence of identifiable organic lesion or dysfunction explains the doubts long expressed by part of the medical profession on the rational basis of this disease. It is possible that these anomalies exist but are not detectable by current exploration techniques. Also, fibromyalgia is no longer considered a psychosomatic illness, but a nociplastic pain caused by alterations in nociception, that is to say in the pain detection and control system.
The FiRST questionnaire is a screening tool for fibromyalgia, simple and easy to use, with good sensitivity and specificity. A score of 5 items out of the 6 items of the questionnaire makes it possible to detect fibromyalgia with a sensitivity of 90.5% and a specificity of 85.7%.